EastWest Bioscience Past Earnings Performance
Past criteria checks 0/6
There is insufficient data on EastWest Bioscience's performance over the last few years.
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
| Pharmaceuticals Industry Growth | 6.0% |
| Revenue growth rate | n/a |
| Return on equity | n/a |
| Net Margin | n/a |
| Last Earnings Update | 30 Apr 2022 |
Recent past performance updates
No updates
Recent updates
No updates
Revenue & Expenses Breakdown
How EastWest Bioscience makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Apr 22 | 1 | 0 | 3 | 0 |
| 31 Jan 22 | 1 | 1 | 3 | 0 |
| 31 Oct 21 | 1 | -2 | 2 | 0 |
| 31 Jul 21 | 1 | -2 | 2 | 0 |
| 30 Apr 21 | 1 | -1 | 1 | 0 |
| 31 Jan 21 | 1 | -1 | 2 | 0 |
| 31 Oct 20 | 1 | -1 | 2 | 0 |
| 31 Jul 20 | 1 | -1 | 2 | 0 |
| 30 Apr 20 | 2 | -2 | 2 | 0 |
| 31 Jan 20 | 2 | -3 | 3 | 0 |
| 31 Oct 19 | 2 | -3 | 3 | 0 |
| 31 Jul 19 | 1 | -4 | 3 | 0 |
| 30 Apr 19 | 1 | -4 | 3 | 0 |
| 31 Jan 19 | 1 | -4 | 3 | 0 |
| 31 Oct 18 | 0 | -4 | 2 | 0 |
| 31 Jul 18 | 0 | -3 | 2 | 0 |
| 30 Apr 18 | 0 | -2 | 1 | 0 |
| 31 Jan 18 | 0 | -1 | 1 | 0 |
| 31 Oct 17 | 0 | -1 | 1 | 0 |
| 31 Jul 17 | 0 | -1 | 1 | 0 |
| 30 Apr 17 | 0 | -1 | 0 | 0 |
| 31 Jan 17 | 0 | -1 | 0 | 0 |
| 31 Oct 16 | 0 | 0 | 0 | 0 |
| 31 Jul 16 | 0 | 0 | 0 | 0 |
Quality Earnings: Insufficient data to determine if HBOS.F has high quality earnings.
Growing Profit Margin: Insufficient data to determine if HBOS.F's profit margins have improved over the past year.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if HBOS.F's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Insufficient data to compare HBOS.F's past year earnings growth to its 5-year average.
Earnings vs Industry: Insufficient data to determine if HBOS.F's earnings growth over the past year exceeded the Pharmaceuticals industry average.
Return on Equity
High ROE: HBOS.F has a negative Return on Equity (0%), as it is currently unprofitable.